openheart Improving CHA₂DS₂-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation

Kevin G Graves,¹ Heidi T May,¹ Kirk U Knowlton,¹ Joseph B Muhlestein,^{1,2} Victoria Jacobs,¹ Donald L Lappé,^{1,2} Jeffrey L Anderson,^{1,2} Benjamin D Horne,^{1,3} Thomas Jared Bunch^{1,4}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2018-000907>).

To cite: Graves KG, May HT, Knowlton KU, *et al.* Improving CHA₂DS₂-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. *Open Heart* 2018;5:e000907. doi:10.1136/openhrt-2018-000907

BDH and TJB contributed equally.

Received 10 August 2018
Revised 27 September 2018
Accepted 4 October 2018

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Thomas Jared Bunch;
thomas.bunch@imail.org

ABSTRACT

Background Oral anticoagulation (OAC) therapy guidelines recommend using CHA₂DS₂-VASc to determine OAC need in atrial fibrillation (AF). A usable tool, CHA₂DS₂-VASc is challenged by its predictive ability. Applying components of the complete blood count and basic metabolic profile, the Intermountain Mortality Risk Score (IMRS) has been extensively validated. This study evaluated whether use of IMRS with CHA₂DS₂-VASc in patients with AF improves prediction.

Methods Patients with AF undergoing cardiac catheterisation (N=10 077) were followed for non-fatal stroke and mortality (mean 5.8±4.1 years, maximum 19 years). CHA₂DS₂-VASc and IMRS were calculated at baseline. IMRS categories were defined based on previously defined criteria. Cox regression was adjusted for demographic, clinical and treatment variables not included in IMRS or CHA₂DS₂-VASc.

Results In women (n=4122, mean age 71±12 years), the composite of non-fatal stroke/mortality was stratified (all p-trend <0.001) by CHA₂DS₂-VASc (1: 12.6%, 2: 22.8%, >2: 48.1%) and IMRS (low: 17.8%, moderate: 40.9%, high risk: 64.5%), as it was for men (n=5955, mean age 68±12 years) by CHA₂DS₂-VASc (<2: 15.7%, 2: 30.3%, >2: 51.8%) and IMRS (low: 19.0%, moderate: 42.0%, high risk: 65.9%). IMRS stratified stroke/mortality (all p-trend <0.001) in each CHA₂DS₂-VASc category.

Conclusions Using IMRS jointly with CHA₂DS₂-VASc in patients with AF improved the prediction of stroke and mortality. For example, in patients at the OAC treatment threshold (CHA₂DS₂-VASc = 2), IMRS provided ≈4-fold separation between low and high risk. IMRS provides an enhancing marker for risk in patients with AF that reflects the underlying systemic nature of this disease that may be considered in combination with the CHA₂DS₂-VASc score.

Atrial fibrillation (AF) is a complex, systemic disease that is marked by structural and electrophysiological remodelling of atrial tissue.¹ AF results in various clinical manifestations with differing symptoms, yet

Key questions

What is already known about the subject?

- The CHADS₂ and CHA₂DS₂-VASc scores are the most widely used models for risk-guided provision of OAC to AF patients.
- A meta-analysis evaluated the CHADS₂ and CHA₂DS₂-VASc scores and reported some of the best c-statistics for these scores at 0.685 and 0.675, respectively; values that suggest limited predictive ability for stroke.
- As such new tools are needed to work with these prior scores or independently that can dynamically assess stroke risk.

What does this study add?

- The sex-specific IMRS derived from commonly ordered physiologic tests and the CHA₂DS₂-VASc score were significant independent risk predictors of a composite of stroke or mortality among AF patients.
- IMRS adds to the CHA₂DS₂-VASc across all risk profiles and has the promise to add dynamic understanding of risk assessment to baseline risk factors.

How might this impact on clinical practice?

- This study serves as a foundation for better modeling of risk in AF patients with a combination of both the CHA₂DS₂-VASc risk score and IMRS.
- Dynamic markers of risk can assist in understanding of severity of individual risk factors, response to therapeutic changes or lifestyle modifications, and can augment or lower risk over time to better identify patients at need for long-term anticoagulation.

all patients with AF are at a higher risk of thromboembolism spanning across multiple comorbid states.² Strokes among patients with AF are associated with greater levels of other morbidities and earlier mortality.³ Oral anticoagulation (OAC) is a mainstay of antithrombotic therapy, and based on

current guidelines, OAC should be provided to patients according to a risk-optimised approach.

The CHADS₂ and CHA₂DS₂-VASc scores are the most widely used models for risk-guided provision of OAC to patients with AF.¹ In recognition of a potential higher-than-expected risk with lower CHA₂DS₂-VASc scores and a more favourable benefit/risk profile with direct oral anticoagulants (DOACs), the most recent European Society of Cardiology guidelines recommend use in patients with a CHA₂DS₂-VASc score of 1 or higher.⁴ A meta-analysis evaluating the CHADS₂ and CHA₂DS₂-VASc scores reported some of the best c-statistics for these scores at 0.685 and 0.675, respectively, although these values suggest limited predictive ability for stroke.⁵ Despite their limitations, these scores are simple to memorise and calculate in one's head and thus are widely used, but by design they sacrifice their predictive ability to be feasible for use in clinical practice.⁶ Additionally, these scores are composed of static, dichotomous baseline variables and as a consequence predict higher risk once risk factors become present regardless of whether the patient's health improves.

A risk prediction tool for clinical decision-making that incorporates pertinent risk information not included by CHADS₂ and CHA₂DS₂-VASc and is feasible to use in clinical practice could improve the precise identification of patients with AF who do, and those who do not, need OAC. The Intermountain Mortality Risk Scores (IMRSs) are potentially such clinical decision tools that have been extensively validated to stratify risk of morbidity and mortality in a wide variety of cardiovascular and non-cardiac patient populations.^{7–9} IMRS models are adaptive and dynamic because they use risk factors that vary over time due to changes (including improvements) in physiological status, pharmacological therapies and lifestyles. This study evaluated whether the combination of CHA₂DS₂-VASc and IMRS can improve risk stratification in the AF population.

METHODS

Study population

The study population consisted of adult patients (ages ≥18) with AF who were evaluated by cardiac catheterisation at the Intermountain Heart Institute from October 1993 through December 2015 and who also had both complete blood count (CBC) and basic metabolic profile (BMP) values measured. This was a retrospective analysis of prospectively collected observational data from the Intermountain Healthcare electronic data warehouse that consists of an electronically mirrored copy of clinical health records for administrative and research use. CHA₂DS₂-VASc was calculated based on previously established criteria¹⁰ and IMRS was computed based on previously derived sex-specific weightings of age and the components of the CBC and BMP laboratory panels.^{7–9 11}

Laboratory analysis and risk calculation

IMRS values were generated using subject age, sex, and CBC and BMP laboratory measurements at the time of inclusion into the study.¹² IMRS was derived in 2009 as a sex-specific linear combination of weighted regression coefficients for the following risk predictors: haematocrit, mean corpuscular volume, red cell distribution width, mean corpuscular haemoglobin concentration, platelet count, mean platelet volume, white blood cell count, sodium, potassium, bicarbonate, creatinine, glucose, calcium and age. CBC panels were analysed on Coulter haematology analysers (Beckman Coulter, Hialeah, Florida, USA) until 2012 or on Sysmex haematology analysers (Sysmex America, Lincolnshire, Illinois, USA) beginning in mid-2012, and reported values were normalised to ensure concordance in the population. BMP panels were tested using a Vitros clinical chemistry system (Ortho Clinical Diagnostics, Raritan, New Jersey, USA).

IMRS scores were calculated for all patients and divided into groups of low, moderate and high risk based on thresholds reported in prior publications.^{9 12} The risk categories for IMRS among men were <11, 11–16 and ≥17, respectively, using the 1-year mortality IMRS formula. For women, IMRS categories of low, moderate and high risk were scores of <9, 9–14 and ≥15, respectively, for 1-year IMRS calculations.

Study endpoints

Due to an inability to obtain cause of death information on approximately one-third of patients and because of the relatively low frequency of non-fatal stroke, the primary outcome in this study was all-cause mortality or non-fatal stroke within pre-specified groups of IMRS and CHA₂DS₂-VASc. Death outcomes were determined from a combination of Intermountain Healthcare electronic records, Social Security Administration death master file and State of Utah death certificates. Stroke outcomes were obtained electronically from Intermountain records based on International Classification of Diseases codes, with both ischaemic and haemorrhagic stroke included in the outcomes under the assumption that any event not predicted by the risk scores in this study would be randomly distributed across risk categories. Those outcomes labelled as stroke were all admissions to a medical facility with a non-fatal stroke. The study cohort was also evaluated for non-fatal stroke and for mortality separately.

Statistical considerations

Survival analyses were performed to evaluate the association of CHA₂DS₂-VASc and of IMRS with study outcomes for up to 19 years of follow-up. Survival curves were generated using the Kaplan-Meier method. Cox proportional-hazards models were constructed separately for men and women to evaluate CHA₂DS₂-VASc and IMRS in univariable analysis and together in bivariable modelling. Cox regression was evaluated for IMRS within

strata defined by CHA₂DS₂-VASC, categorised by previously derived thresholds of low, medium or high risk for mortality.^{9 12} Cox regression was also used to evaluate multivariable adjusted associations of the risk scores with outcomes for 20 variables that were not included in the risk scores (hyperlipidemia, family history of coronary disease, history of or current smoking, presentation (unstable angina or acute myocardial infarction), history of renal failure, chronic obstructive pulmonary disease, depression, number of diseased coronary arteries (70% or greater stenosis), treatment with ablation, treatment with percutaneous coronary intervention or coronary bypass surgery, and discharge prescription of an anticoagulant, aspirin, antiplatelet, statin, beta-blocker, calcium channel blocker, diabetes medication, diuretic, ACE inhibitor or angiotensin receptor blocker).

Stratified analyses were performed in which IMRS associations with study outcomes were evaluated in CHA₂DS₂-VASC categories defined by scores ≤1, 2 and ≥3. Kaplan-Meier survival curves were created for IMRS risk groupings within each of those CHA₂DS₂-VASC strata. Cox regressions for the association of IMRS with outcomes were performed as described above but within CHA₂DS₂-VASC categories and for the association of joint CHA₂DS₂-VASC/IMRS categories instead of with CHA₂DS₂-VASC included in the modelling. The receiver operator characteristic curve was evaluated to determine c-statistics describing the predictive ability of risk scores for study outcomes. Predictive values were calculated for positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity and accuracy. Two-sided statistical tests were evaluated using SPSS V.23 (IBM SPSS Statistics) with a p value of ≤0.05 designated as statistically significant.

RESULTS

Baseline characteristics of women (n=4122) and men (n=5955) are shown in table 1. The composite of non-fatal stroke or mortality was predicted among women by CHA₂DS₂-VASC categories (1: 12.6%, 2: 22.8%, >2: 48.1%; p-trend <0.001) and by IMRS (low-risk: 17.8%, moderate-risk: 40.9%, high-risk: 64.5%; p-trend <0.001). This was also the case for men, with both CHA₂DS₂-VASC (<2: 15.7%, 2: 30.3%, >2: 51.8%; p-trend <0.001) and IMRS (low risk: 19.0%, moderate risk: 42.0%, high risk: 65.9%) predicting the primary outcome. Kaplan-Meier survival curves displaying these outcomes are shown in figure 1. In Cox regression entering both IMRS and CHA₂DS₂-VASC (table 2), both risk scores remained significant among both women and men, although the association of CHA₂DS₂-VASC with stroke or mortality was reduced compared with univariable analysis (beta-coefficients for CHA₂DS₂-VASC of 2 and >2 in women and men were reduced by 30%–37% in bivariable analyses). Changes to the association of IMRS with outcomes were impacted less (beta-coefficients for IMRS in Cox regression were 16%–27% lower for moderate and high-risk groups

Table 1 Baseline characteristics

Characteristic	(n=4122)	(n=5955)
	Women	Men
Risk scores		
IMRS		
Low risk	24.20%	39.90%
Moderate risk	51.70%	46.90%
High risk	24.00%	13.30%
CHA₂DS₂-VASC		
0	–	11.40%
1	8.90%	18.50%
2	15.80%	24.60%
≥3	75.30%	45.50%
CHA₂DS₂-VASC factors		
HF history	28.90%	30.20%
Hypertension history	48.30%	
Age (years)	71±12	68±12
Diabetes	31.50%	31.60%
Stroke history	5.50%	3.70%
Prior MI	4.60%	6.90%
Peripheral vascular disease	1.10%	1.20%
Other morbidities and risk factors		
Hyperlipidemia history	30.00%	37.60%
Smoking (ever)	6.30%	12.70%
Ablation at study entry	20.10%	21.40%
ACS at study entry	17.40%	22.10%
Coronaries with significant disease		
0	78.50%	66.30%
1	8.90%	10.60%
2	6.10%	10.30%
3	6.50%	12.80%
PCI or CABG at study entry	16.60%	26.00%
Family history of early CAD	13.90%	16.30%
Renal failure history	1.40%	1.60%
COPD history	1.30%	1.20%
Depression history	16.30%	7.00%
Medication prescriptions		
Anticoagulant	51.10%	51.00%
Aspirin	64.30%	69.70%
Antiplatelet	48.60%	58.10%
Beta-blocker	35.60%	41.70%
Calcium channel blocker	15.60%	11.90%
Diuretic	44.50%	42.10%
ACE inhibitor	22.60%	29.40%
Angiotensin receptor blocker	10.40%	8.00%
Antidiabetic medication	20.80%	22.60%
Statin	38.60%	49.50%

ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; IMRS, Intermountain Mortality Risk Score; MI, myocardial infarction; PCI, percutaneous coronary intervention.

in women and men). Results were similar to this after further multivariable adjustment in Cox regression.

Evaluation of predictive ability for women found c-statistics of c=0.683 for CHA₂DS₂-VASC and c=0.706 for IMRS

Figure 1 Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend <0.001, low risk: n=996, moderate risk: n=2129, high risk: n=997) and (B) men (p-trend <0.001, low risk: n=2373, moderate risk: n=2791, high risk: n=791), and CHA₂DS₂-VASc categories among (C) women (p-trend <0.001, 1: n=357, 2: n=648, >2: n=3117) and (D) men (p-trend <0.001, 0: n=659, 1: n=1088, 2: n=1463, >2: n=2745). IMRS, Intermountain Mortality Risk Score.

for stroke or mortality. For men, c-statistics were $c=0.706$ for CHA₂DS₂-VASc and $c=0.716$ for IMRS. The PPV, NPV, sensitivity, specificity and accuracy for women and men are shown in online supplementary table s1, including for the composite endpoint and for each endpoint individually, demonstrating poor PPV (as is typical for all prognostic scores) and limited other predictive value except for sensitivity when examining the combined intermediate and high-risk groups. Examination of the high-risk groups compared with the low-risk and intermediate-risk groups revealed that both CHA₂DS₂-VASc and IMRS had strong NPV and specificity but limited PPV and sensitivity.

IMRS provided further significant stratification of the risk of stroke/mortality within each CHA₂DS₂-VASc category, as demonstrated in figure 2 for women and figure 3 for men. This may be especially important in those with CHA₂DS₂-VASc scores not meeting guidelines for OAC (CHA₂DS₂-VASc<2) and in those just barely meeting guideline to receive OAC (CHA₂DS₂-VASc=2). For women with CHA₂DS₂-VASc=1, IMRS had fully adjusted HR=2.40 (CI 1.21 to 4.79) for moderate risk versus low risk and HR=6.87 (CI 2.03 to 23.21) for high versus low risk, while for those with CHA₂DS₂-VASc=2 IMRS had HR=1.57 (CI 1.08 to 2.29) for moderate versus low risk

and HR=4.03 (CI 2.31 to 7.02) for high versus low risk. In men, those having CHA₂DS₂-VASc <2 were further risk stratified by IMRS with fully adjusted HR=2.14 (CI 1.65 to 2.77) for moderate versus low risk and HR=6.73 (CI 4.34 to 10.46) for high versus low risk, while among those with CHA₂DS₂-VASc=2, IMRS had HR=1.87 (CI 1.50 to 2.33) for moderate versus low risk and HR=3.62 (CI 2.65 to 4.96) for high versus low risk. In the CHA₂DS₂-VASc >2 category, IMRS also provided additional fully adjusted predictive ability among both women (moderate vs low risk: HR 2.00, CI 1.64 to 2.45; high vs low risk: HR 4.28, CI 3.46 to 5.29) and men (moderate vs low risk: HR 1.82, CI 1.56 to 2.14; high vs low-risk: HR 3.60, CI 3.02 to 4.30). For univariable Cox regression using the joint combination of CHA₂DS₂-VASc and IMRS categories, with all compared with the referent category of <2/low risk, higher HRs in higher risk score categories were found for stroke/mortality, mortality and most analyses for non-fatal stroke (table 3). Small sample sizes, especially in women with CHA₂DS₂-VASc=1, impacted the non-fatal stroke analyses.

These stratified findings were replicated within further stratifications defined by whether or not patients were prescribed an OAC at discharge (online supplementary

Table 2 Cox regression of IMRS and CHA₂DS₂-VASC associations with non-fatal stroke or mortality and with each endpoint individually

Sex	Independent predictors	Univariable HR (95% CI)	Bivariable HR (95% CI)	Multivariable HR (95% CI)
Primary study endpoint: non-fatal stroke or all-cause mortality				
Women				
	IMRS, moderate vs low risk	2.81 (2.39 to 3.30)*	2.21 (1.87 to 2.61)*	2.04 (1.72 to 2.42)*
	IMRS, high vs low risk	7.14 (6.03 to 8.45)*	5.19 (4.35 to 6.20)*	4.46 (3.71 to 5.35)*
	CHA ₂ DS ₂ -VASC, 2 vs 1	1.81 (1.30 to 2.53)*	1.50 (1.08 to 2.10)†	1.45 (1.04 to 2.03)†
	CHA ₂ DS ₂ -VASC, >2 vs 1	4.94 (3.67 to 6.65)*	2.75 (2.03 to 3.73)*	2.46 (1.81 to 3.35)*
Men (CHA ₂ DS ₂ -VASC low-risk category based on European guidelines)				
	IMRS, moderate vs low risk	2.87 (2.57 to 3.20)*	2.06 (1.84 to 2.31)*	1.86 (1.66 to 2.09)*
	IMRS, high vs low risk	7.25 (6.38 to 8.25)*	4.54 (3.96 to 5.21)*	3.67 (3.19 to 4.23)*
	CHA ₂ DS ₂ -VASC, 1 vs 0	2.89 (2.13 to 3.93)*	2.42 (1.77 to 3.31)*	2.22 (1.62 to 3.05)*
	CHA ₂ DS ₂ -VASC, 2 vs 0	4.83 (3.61 to 6.48)*	3.48 (2.58 to 4.71)*	3.05 (2.25 to 4.15)*
	CHA ₂ DS ₂ -VASC, >2 vs 0	9.78 (7.38 to 12.97)*	5.74 (4.27 to 7.71)*	4.61 (3.40 to 6.26)*
Men (CHA ₂ DS ₂ -VASC low-risk category based on American guidelines)				
	IMRS, moderate vs low risk	2.87 (2.57 to 3.20)*	2.15 (1.92 to 2.41)*	1.99 (1.77 to 2.23)*
	IMRS, high vs low risk	7.25 (6.38 to 8.25)*	4.72 (4.12 to 5.41)*	4.10 (3.56 to 4.72)*
	CHA ₂ DS ₂ -VASC, 2 vs <2	2.25 (1.94 to 2.62)*	1.77 (1.52 to 2.06)*	1.71 (1.46 to 2.00)*
	CHA ₂ DS ₂ -VASC, >2 vs <2	4.55 (4.00 to 5.18)*	2.90 (2.53 to 3.33)*	2.80 (2.42 to 3.23)*
Secondary study endpoint: non-fatal stroke				
Women				
	IMRS, moderate vs low risk	1.19 (0.88 to 1.60)	0.96 (0.70 to 1.32)	0.92 (0.67 to 1.26)
	IMRS, high vs low risk	1.44 (0.99 to 2.10)	1.08 (0.73 to 1.61)	0.96 (0.64 to 1.45)
	CHA ₂ DS ₂ -VASC, 2 vs 1	1.19 (0.63 to 2.24)	1.19 (0.63 to 2.26)	1.10 (0.58 to 2.09)
	CHA ₂ DS ₂ -VASC, >2 vs 1	2.18 (1.27 to 3.75)†	2.17 (1.24 to 3.82)†	1.87 (1.08 to 3.24)†
Men (CHA ₂ DS ₂ -VASC low-risk category based on European guidelines)				
	IMRS, moderate vs low risk	1.39 (1.07 to 1.82)†	1.05 (0.80 to 1.39)	1.01 (0.76 to 1.33)
	IMRS, high vs low risk	2.86 (2.01 to 4.07)*	1.92 (1.33 to 2.78)*	1.68 (1.15 to 2.44)†
	CHA ₂ DS ₂ -VASC, 1 vs 0	4.36 (1.97 to 9.66)*	4.25 (1.92 to 9.43)*	4.17 (1.87 to 9.29)*
	CHA ₂ DS ₂ -VASC, 2 vs 0	4.39 (2.00 to 9.62)*	4.15 (1.88 to 9.15)*	4.13 (1.86 to 9.17)*
	CHA ₂ DS ₂ -VASC, >2 vs 0	7.76 (3.64 to 16.54)*	6.79 (3.13 to 14.70)*	6.87 (3.15 to 15.01)*
Men (CHA ₂ DS ₂ -VASC low-risk category based on American guidelines)				
	IMRS, moderate vs low risk	1.39 (1.07 to 1.82)†	1.11 (0.84 to 1.47)	1.07 (0.81 to 1.41)
	IMRS, high vs low risk	2.86 (2.01 to 4.07)*	2.02 (1.39 to 2.93)*	1.84 (1.27 to 2.69)†
	CHA ₂ DS ₂ -VASC, 2 vs <2	1.45 (0.99 to 2.10)	1.37 (0.94 to 2.00)	1.32 (0.90 to 1.93)
	CHA ₂ DS ₂ -VASC, >2 vs <2	2.55 (1.87 to 3.48)*	2.22 (1.59 to 3.09)*	2.19 (1.56 to 3.08)*
Secondary study endpoint: all-cause mortality				
Women				
	IMRS, moderate vs low risk	3.40 (2.83 to 4.07)*	2.65 (2.19 to 3.19)*	2.43 (2.01 to 2.94)*
	IMRS, high vs low risk	9.21 (7.64 to 11.11)*	6.62 (5.44 to 8.05)*	5.67 (4.62 to 6.94)*
	CHA ₂ DS ₂ -VASC, 2 vs 1	2.03 (1.39 to 2.94)*	1.62 (1.11 to 2.35)†	1.56 (1.07 to 2.28)†
	CHA ₂ DS ₂ -VASC, >2 vs 1	5.94 (4.24 to 8.30)*	3.03 (2.15 to 4.28)*	2.80 (1.98 to 3.96)*
Men (CHA ₂ DS ₂ -VASC low-risk category based on European guidelines)				
	IMRS, moderate vs low risk	3.19 (2.84 to 3.58)*	2.26 (2.00 to 2.55)*	2.04 (1.81 to 2.30)*
	IMRS, high vs low risk	8.30 (7.25 to 9.49)*	5.10 (4.42 to 5.88)*	4.16 (3.59 to 4.81)*
	CHA ₂ DS ₂ -VASC, 1 vs 0	2.84 (2.04 to 3.96)*	2.34 (1.67 to 3.29)*	2.12 (1.51 to 2.99)*
	CHA ₂ DS ₂ -VASC, 2 vs 0	5.18 (3.79 to 7.10)*	3.61 (2.61 to 5.00)*	3.12 (2.24 to 4.34)*

Continued

Table 2 Continued

Sex	Independent predictors	Univariable HR (95% CI)	Bivariable HR (95% CI)	Multivariable HR (95% CI)
	CHA ₂ DS ₂ -VASC, >2 vs 0	10.83 (7.99 to 14.67)*	6.06 (4.41 to 8.33)*	4.75 (3.43 to 6.60)*
Men (CHA ₂ DS ₂ -VASC low-risk category based on American guidelines)				
	IMRS, moderate vs low risk	3.19 (2.84 to 3.58)*	2.36 (2.09 to 2.66)*	2.16 (1.91 to 2.44)*
	IMRS, high vs low risk	8.30 (7.25 to 9.49)*	5.29 (4.59 to 6.10)*	4.60 (3.97 to 5.32)*
	CHA ₂ DS ₂ -VASC, 2 vs <2	2.44 (2.08 to 2.86)*	1.87 (1.59 to 2.21)*	1.79 (1.52 to 2.11)*
	CHA ₂ DS ₂ -VASC, >2 vs <2	5.10 (4.34 to 5.85)*	3.14 (2.71 to 3.63)*	2.97 (2.55 to 3.46)*

IMRS, Intermountain Mortality Risk Score.

figures s1 and s2). Formal analyses of statistical interactions between OAC and IMRS or CHA₂DS₂-VASC scores showed no interaction (among women and men, all p-interaction were p>0.10 and up to p=0.86). OACs were associated with stroke/mortality only among women in multivariable models (HR 0.90, CI 0.81 to 0.999, p=0.0496; which arose only from an association with mortality: HR 0.88, CI 0.79 to 0.98, p=0.018), but they were not associated with stroke/mortality or mortality in men and were not associated with non-fatal stroke in either sex.

For non-fatal stroke individually, CHA₂DS₂-VASC (women—1: 3.9%, 2: 4.6%, >2: 6.6%, p-trend <0.001; men—<2: 3.1%, 2: 3.9%, >2: 5.8%, p-trend <0.001) and IMRS (women—low risk: 6.4%, moderate risk: 6.4%, high risk: 4.9%, p-trend=0.06; men—low risk: 4.1%, moderate risk: 4.6%, high risk: 6.0%, p-trend <0.001) predicted non-fatal stroke. However, for women, the predictive ability was not different from chance (c=0.480), while for IMRS in men (c=0.526) and CHA₂DS₂-VASC for both sexes (women: c=0.573; men: c=0.596), the predictive

Figure 2 Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA₂DS₂-VASC score of (A) 1 (p-trend <0.001, IMRS<9: n=251, 9–14: n=97, ≥15: n=9), (B) 2 (p-trend <0.001, IMRS<9: n=312, 9–14: n=296, ≥15: n=40) and (C) >2 (p-trend <0.001, IMRS<9: n=433, 9–14: n=1736, ≥15: n=948). IMRS, Intermountain Mortality Risk Score.

Figure 3 Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in men with AF, stratified by CHA₂DS₂-VASc of (A) 0 (p-trend <0.001, IMRS<11: n=543, 11-16: n=108, ≥17: n=8), (B) 1 (p-trend <0.001, IMRS<11: n=653, 11-16: n=390, ≥17: n=45), (C) 2 (p-trend <0.001, IMRS<11: n=594, 11-16: n=741, ≥17: n=128) and (D) >2 (p-trend <0.001, IMRS<11: n=583, 11-16: n=1553, ≥17: n=609).

ability was minimal. In bivariable Cox regression analyses for non-fatal stroke alone (table 2), CHA₂DS₂-VASc but not IMRS remained significant among women, while the higher but not intermediate categories of both risk scores were significant predictors among men. Cox regression for joint risk score categories further elucidated the combined associations with non-fatal stroke (table 3).

For mortality alone, CHA₂DS₂-VASc (women—1: 9.8%, 2: 19.9%, >2: 44.9%, p-trend <0.001; men—<2: 13.5%, 2: 28.2%, >2: 49.9%, p-trend <0.001) and IMRS (women—low risk: 13.7%, moderate risk: 37.8%, high risk: 62.6%, p-trend <0.001; men—low risk: 16.2%, moderate risk: 40.2%, high risk: 64.6%, p-trend <0.001) predicted the outcome. For mortality, table 2 shows that both risk scores were strongly significant predictors in both women and men, with c=0.730 for IMRS and c=0.685 for CHA₂DS₂-VASc among women and c=0.730 for IMRS and c=0.713 for CHA₂DS₂-VASc among men. See table 3 for joint risk score associations with mortality.

DISCUSSION

The sex-specific IMRS and the CHA₂DS₂-VASc score were significant independent risk predictors of a composite of stroke or mortality among patients with AF. The two

scores also predicted the individual endpoints, with both predicting non-fatal stroke among men and mortality among men and women. As further evidence of their independent ability to predict risk, IMRS added to risk stratification when examined within substrata defined by CHA₂DS₂-VASc levels. These findings add patients with AF to the populations for which IMRS is a validated predictor of risk.^{4,7,8} With respect to the clinical application of IMRS, patients with AF with a CHA₂DS₂-VASc score at or above 2 had significant additional discrimination of risk across IMRS categories that could be useful in evaluation of which patients with AF require OAC. This included that some patients with a CHA₂DS₂-VASc score <2 were identified to have a significantly higher risk when IMRS was included in risk stratification (see figures 2A, 3A and B) than clinically is estimated today by use of just CHA₂DS₂-VASc. Among patients where CHA₂DS₂-VASc suggests that OAC is indicated, IMRS identified patients with AF who were at a substantially lower risk than the CHA₂DS₂-VASc estimate indicated, including in those with a CHA₂DS₂-VASc score of 2.

IMRS is a validated risk prediction tool that has the ability to provide discrete information regarding pathological and metabolic pathways.¹² This prediction tool uses

Table 3 HRs and 95% CI (bold/italicised: $p < 0.05$) for the association of joint CHA₂DS₂-VASc and IMRS categories with non-fatal stroke/mortality, non-fatal stroke and mortality

CHA ₂ DS ₂ -VASc score		CHA ₂ DS ₂ -VASc score	
IMRS risk	1	2	>2
Women			
Non-fatal stroke/mortality			
Low	Referent	1.71 (1.02 to 2.89)	3.01 (1.87 to 4.84)
Moderate	2.47 (1.34 to 4.56)	3.40 (2.08 to 5.55)	6.69 (4.29 to 10.43)
High	8.85 (3.02 to 25.90)	10.25 (5.59 to 18.78)	15.47 (9.90 to 24.16)
Non-fatal stroke			
Low	Referent	1.09 (0.47 to 2.56)	2.58 (1.26 to 5.30)
Moderate	1.07 (0.32 to 3.47)	1.52 (0.67 to 3.45)	2.23 (1.13 to 4.39)
High	5.12 (0.65 to 40.43)	1.05 (0.13 to 8.27)	2.54 (1.24 to 5.18)
Mortality			
Low	Referent	1.93 (1.04 to 3.56)	3.27 (1.86 to 5.76)
Moderate	3.04 (1.51 to 6.12)	4.37 (2.46 to 7.75)	8.87 (5.23 to 15.06)
High	8.95 (2.57 to 31.16)	13.24 (6.73 to 26.04)	21.93 (12.90 to 37.28)
Men			
Non-fatal stroke/mortality			
Low	Referent	2.04 (1.59 to 2.61)	3.38 (2.71 to 4.21)
Moderate	2.48 (1.94 to 3.19)	4.12 (3.33 to 5.08)	6.93 (5.75 to 8.35)
High	8.01 (5.29 to 12.13)	9.40 (6.97 to 12.67)	14.82 (12.15 to 18.06)
Non-fatal stroke			
Low	Referent	1.21 (0.69 to 2.13)	2.87 (1.83 to 4.48)
Moderate	1.35 (0.76 to 2.42)	1.94 (1.20 to 3.14)	2.45 (1.63 to 3.67)
High	3.32 (1.02 to 10.81)	2.55 (1.00 to 6.54)	4.82 (3.03 to 7.67)
Mortality			
Low	Referent	2.28 (1.74 to 2.98)	3.68 (2.89 to 4.70)
Moderate	2.81 (2.14 to 3.68)	4.77 (3.79 to 6.01)	8.43 (6.87 to 10.35)
High	8.95 (5.79 to 13.86)	11.96 (8.76 to 16.32)	18.24 (14.69 to 22.65)

IMRS, Intermountain Mortality Risk Score.

components of the CBC and BMP, and has illuminated the broader risk implications that are present within these commonly ordered tests. Originally created to predict mortality in a general population, IMRS reflects underlying pathophysiology that presents itself in patients as a constellation of factors that result in systemic vascular dysfunction. It is suspected that AF is a manifestation of underlying systemic vascular disease.¹³ One of the strongest drivers of IMRS is the red cell distribution width, which is associated with many diseases and may serve well as a marker for many underlying pathophysiologies.¹⁴ The mechanism behind this relationship is not entirely known, but the red cell distribution width may serve as a strong marker of risk regardless of whether we understand the biology at this time. IMRS also uses essentially all other components of the CBC and BMP, which give a broader view of the underlying metabolic and pathological pathways, although the risk weightings vary in strength for the various score components. For example, platelets, platelet receptors and adhesion molecules all play a critical role in coronary artery disease,¹⁵ and white blood cell count is also a well-established marker of general inflammation.

The argument for starting a patient with AF on OAC at a specific CHA₂DS₂-VASc score threshold is based on recommendations of society guidelines. These recommendations are based on studies that suggest the CHA₂DS₂-VASc more clearly defines risk than the CHADS₂ score and redistributed more patients from a low-risk to a high-risk group.^{10 16 17} This shift from the CHADS₂ to CHA₂DS₂-VASc score is largely based on removing the large intermediate-risk group found with CHADS₂, where anticoagulation recommendations were not very clear.¹⁷ The result was a large shift of women, particularly older women, to the high-risk group. Unfortunately, while older women have a heightened risk of stroke, they are also at a higher risk for bleeds. It is also suggested that CHA₂DS₂-VASc was a better discriminator of 'true low-risk' patients when compared with CHADS₂.¹⁶ This is important as the net benefit analyses have shown only patients who truly do not benefit from OAC are those at low risk for stroke, even when taking bleeding risk into account.¹⁸ While CHADS₂ and CHA₂DS₂-VASc are the most widely used measures to determine use of OAC in patients with AF, it is readily apparent that they are challenged by their lack of discernment between low-risk, intermediate-risk and high-risk patients, as well as a lack of dynamicity. While a study showed that CHA₂DS₂-VASc can increase over time,⁽²⁹⁾ this only occurs when a risk factor that a patient did not already have is diagnosed, while laboratory factors can increase and also decrease and may improve in response to a successful treatment. By current guidelines, patients with a score >1 should receive OAC. In this cohort, that accounts for 91.1% of women and 70.1% of men (88.6% of men when a score of 1 is included in the high-risk group).

IMRS exhibited stronger specificity as well as stronger NPV than CHA₂DS₂-VASc in this cohort of patients. The augmentation of risk stratification can be useful to clinicians when dealing with an intermediate-risk patient (as

defined by CHA₂DS₂-VAsC). A low IMRS when combined with a CHA₂DS₂-VAsC score of 2 showed a near fourfold lower risk compared with a patient with a high IMRS in the same CHA₂DS₂-VAsC strata. Similarly, lower risk was noted for high versus low IMRS in CHA₂DS₂-VAsC score of 1. Discernment of truly low-risk patients in this 'intermediate-risk' group represents an opportunity for low-risk patients to put off initiation of OAC until their risk profile increases to a level more commensurate with OAC initiation. A similar approach may be considered for OAC initiation in a patient stratified as low risk by CHA₂DS₂-VAsC but with a high IMRS.

LIMITATIONS

This was a retrospective, observational study that used historically collected data entered by physicians from patients who presented for cardiac catheterisation. Hence, this study may include unobserved or uncontrolled confounding that could limit the generalisability of the results. For example, a minority of these patients with AF presented with acute coronary syndromes which may alter laboratory values transiently, although such changes may be prognostic compared with patients with non-acute coronary syndromes. Furthermore, the patients included in this study were higher-risk individuals with a clinical indication for cardiac catheterisation, thus the results reported herein may not be generalisable to the general AF population. Also, the extent to which adding these risk scores improves predictive accuracy in therapeutic decision-making for this patient cohort requires additional study.

CONCLUSIONS

Using IMRS jointly with CHA₂DS₂-VAsC in patients with AF improved the prediction of stroke and mortality. For example, in patients at the OAC treatment threshold (CHA₂DS₂-VAsC=2), IMRS provided ≈4-fold separation between low and high risk. IMRS provides an enhancing marker for risk in patients with AF that reflects the underlying systemic nature of this disease that may be considered in combination with the CHA₂DS₂-VAsC score.

Author affiliations

¹Intermountain Heart Institute, Intermountain Medical Center, Murray, Utah, USA

²Cardiology Division, Department of Internal Medicine, University of Utah, Murray, Utah, USA

³Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, USA

⁴Department of Internal Medicine, Stanford University, Palo Alto, California, USA

Contributors BDH and TJB designed the study. KGG, HTM, VJ, BDH and TJB planned the execution of the study. BDH and HTM collected and prepared the data. BDH conducted statistical analyses. KGG, HTM, KUK, JBM, VJ, DLL, JLA, BDH and TJB evaluated and interpreted the results. KGG, VJ, BDH and TJB drafted the manuscript. HTM, KUK, JBM, DLL and JLA revised the paper for important intellectual content.

Funding This work was supported by internal institutional funds and the authors had final authority over manuscript content.

Competing interests BDH is an inventor of IMRS and other risk scores that are licensed to CareCentra. BDH is PI of grants funded by Intermountain Healthcare's Foundry innovation program, the Intermountain Research and Medical Foundation, CareCentra, AstraZeneca and GlaxoSmithKline for the development and/or

implementation of clinical risk scores. The authors have no other potential conflicts of interest to report.

Patient consent Not required.

Ethics approval This study was approved by the Intermountain Healthcare Institutional Review Board as a minimum-risk study.

Provenance and peer review Not commissioned; internally peer reviewed.

Data sharing statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0>

REFERENCES

1. January CT, Wann LS, Alpert JS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation* 2014;130:2071–104.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. *Circulation* 2013;127:e6–245.
3. Hannon N, Daly L, Murphy S, et al. Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: population-based study. *Stroke* 2014;45:3670–4.
4. Horne BD, Budge D, Masica AL, et al. Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization. *Am Heart J* 2017;185:101–9.
5. Chen JY, Zhang AD, Lu HY, et al. CHADS2 versus CHA2DS2-VAsC score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. *J Geriatr Cardiol* 2013;10:258–66.
6. Kim MN, Kim SA, Choi JI, et al. Improvement of predictive value for thromboembolic risk by incorporating left atrial functional parameters in the CHADS2 and CHA2DS2-VAsC scores. *Int Heart J* 2015;56:286–92.
7. Horne BD, Anderson JL, Muhlestein JB, et al. Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. *Eur J Prev Cardiol* 2015;22:519–26.
8. Horne BD, Hegewald M, Muhlestein JB, et al. Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. *Respir Care* 2015;60:1314–23.
9. Horne BD, May HT, Kfoury AG, et al. The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. *Eur J Heart Fail* 2010;12:1203–13.
10. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.
11. Yoon M, Yang PS, Jang E, et al. Dynamic Changes of CHA2DS2-VAsC Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. *Thromb Haemost* 2018;118:1296–304.
12. Horne BD, May HT, Muhlestein JB, et al. Exceptional mortality prediction by risk scores from common laboratory tests. *Am J Med* 2009;122:550–8.
13. Bunch TJ, May HT. Atrial fibrillation: a risk factor or risk marker? *Eur Heart J* 2016;37:2890–2.
14. Ycas JW, Horrow JC, Horne BD. Persistent increase in red cell size stratification width after acute diseases: a biomarker of hypoxemia? *Clin Chim Acta* 2015;448:107–17.
15. Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. *Coron Artery Dis* 2003;14:65–79.
16. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VAsC score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. *Thromb Haemost* 2012;107:1172–9.
17. Mason PK, Lake DE, DiMarco JP, et al. Impact of the CHA2DS2-VAsC score on anticoagulation recommendations for atrial fibrillation. *Am J Med* 2012;125:603.e1–603.e6.
18. Shahid F, Lip GYH. Risk stratification models in atrial fibrillation. *Semin Thromb Hemost* 2017;43:505–13.